Septerna

  Season’s Greetings from all of us at Septerna. We wish you a wonderful holiday season and a prosperous 2025!   #Season's Greetings #Happy Holidays

Jeff Finer, chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco. A live webcast will be available in the Investors & Media section of our website: https://lnkd.in/gm-xxXyz #JPM2025

Our Annual Friendsgiving Celebration 2024 was a wonderful success, filled with laughter and delicious food, including a pie-baking contest! This event has become a beloved tradition, bringing everyone together to celebrate camaraderie, gratitude, and continues to strengthen the sense of community within our team.     Here’s wishing everyone a Happy Thanksgiving!   #team #culture #Thanksgiving #gratitude

Thank you, Nasdaq, for the incredible opportunity to ring the Opening Bell! It was an unforgettable moment to celebrate Septerna’s IPO thanks to our dedicated team, investors, and supporters. This milestone marks the beginning of an exciting new chapter as we work to unlock the potential of GPCR-targeted therapies and transform patient care. We’re proud to join the NASDAQ family as $SEPN! #Biotech #NASDAQListed

What a monumental day for Septerna! We rang the Nasdaq Opening Bell today in celebration of our #IPO and the start of an exciting new chapter. With our public listing as $SEPN, we’re well positioned to accelerate the development of our GPCR-targeted therapies. This achievement wouldn’t have been possible without the hard work of our talented team, the support of our broad network of partners, and the trust of our investors. Together, we’re dedicated to bringing future medicines to patients! #NASDAQ #OpeningBell #GoingPublic #Biotech #Innovation

At the American Society for Bone and Mineral Research (ASBMR) Annual Meeting 2024 this weekend, we shared some exciting data supporting clinical development for our oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist program. SEP-786, our lead candidate, is currently being evaluated in a Phase 1 clinical trial for the treatment of hypoparathyroidism. The data presented also highlights and reaffirms the unique ability of our Native Complex  Platform™ to successfully target GPCRs and create potential therapies for difficult to treat diseases. Read more: https://lnkd.in/g8W2CWDa View the poster: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://lnkd.in/g3vWZY_E #ASBMR 2024

This exciting announcement marks Septerna’s transition to a clinical-stage company. SEP-786 is an oral small molecule PTH1R agonist that has the potential to transform hypoparathyroidism patients’ lives by simplifying their daily treatments and improving the overall quality of their lives. Learn more at: https://lnkd.in/gHyeMZav

We are thrilled to welcome to our team Jae Kim, M.D., FACC, as Chief Medical Officer; Monica Gangal as Vice President of Clinical Operations; and Matthew Holdren, Ph.D., DABT, as Vice President of Toxicology! These accomplished executives bring strong individual and combined experience in both biotech and pharma organizations that will be key to Septerna as we transition into a clinical stage organization. Welcome to the team! Read more at: https://lnkd.in/gswwxQp4

We’re thrilled to welcome our newest team members! Your expertise in DMPK, Disease Biology, Computational Chemistry, Protein Science, and G&A will be invaluable as we work together to drive innovation and Make Things Happen! Sunny Tang Lara Tadios Dahlia Weiss Debra Newsome Jonathan Wang Wendy Wang

July is #GravesDiseaseAwarenessMonth. People living with Graves' disease face difficult choices with current treatments, often having to sacrifice one health goal for another. Patients choosing surgery for remission must rely on lifelong thyroid supplementation, while those opting for radiation risk developing or worsening of ophthalmopathy. Antithyroid drugs are often the best option, but are associated with a high rate of relapse. There is an urgent need for better treatment options that can address the challenges effectively. At Septerna, we are committed to providing hope for new therapeutic options that can help patients meet their treatment goals. Learn more: https://bit.ly/4eVjEbc #drugdiscovery